T2DM (Type 2 Diabetes Mellitus) is a significant metabolic condition.The Sodium-Glucose Co-transporter 2 inhibitor (SGLT2i) is an efficient glucose lowering agent in the treatment of type-2-diabetes mellitus (T2DM). They have a potent glucose lowering action, which is insulin independent and shows no glucose energy due to loss of urinary glucose. Sodium-glucose co-transporter-2 drugs restrict glucose reabsorption and allow glucose efflux in the urine via inhibiting SGLT2 in the proximal convoluted tubule (PCT). This study shows the beneficial effects and risks such as genitourinary tract infections, Diabetic ketoacidosis, Postural hypotension, Volume depletion, Dyslipidemia, Lower limb amputation, Skeletal fractures, Acute kidney injury. Patients benefit from sodium glucose co-transporter inhibitors when given as a preventive measure in heart failure or any cardiac complications with diabetes mellitus, patients had optimum glycaemic control when Sodium glucose co-transporter 2 inhibitors (SGLT2i) are given as it also has an advantage of weight loss in obese patients, as well as decrease blood pressure. Safety concerns must be said regarding the occurrence of genitourinary tract infections, although they are caused to the mild to moderate level, prefer to recur and lastly lead to discontinuation of the treatment. A caution to the patients who are sodium glucose co-transporter 2 inhibitors along with NSAIDS or RAS inhibitors, they are highly recommended to monitor renal function closely during the course of treatment.